Partnership And CollaborationsWith a potential partnership upcoming for CUE-501 and a cash position of $22.5MM, Cue remains an attractive investment opportunity with upside potential if a partnership materializes.

Product DevelopmentCue regained the global rights for CUE-401 from Ono and expects to submit an IND, indicating progress in their product development pipeline.

Bears Say

Clinical Development ChallengesThe presence of confounding variables and lack of a partner may hinder the clinical development progress of CUE-101.

Program DeprioritizationThe company has deprioritized its oncology programs, which may impact its current focus and resources.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.26% Insiders

4.03% Mutual Funds

4.46% Other Institutional Investors

87.06% Public Companies and

Individual Investors

Detailed Ownership Overview >

CUE FAQ

What was Cue Biopharma’s price range in the past 12 months?

Cue Biopharma lowest stock price was $0.45 and its highest was $1.99 in the past 12 months.

What is Cue Biopharma’s market cap?

Cue Biopharma’s market cap is $66.53M.

When is Cue Biopharma’s upcoming earnings report date?

Cue Biopharma’s upcoming earnings report date is Sep 08, 2025 which is in 42 days.

How were Cue Biopharma’s earnings last quarter?

Cue Biopharma released its earnings results on May 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.17.

Is Cue Biopharma overvalued?

According to Wall Street analysts Cue Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cue Biopharma pay dividends?

Cue Biopharma does not currently pay dividends.

What is Cue Biopharma’s EPS estimate?

Cue Biopharma’s EPS estimate is -0.13.

How many shares outstanding does Cue Biopharma have?

Cue Biopharma has 75,349,884 shares outstanding.

What happened to Cue Biopharma’s price movement after its last earnings report?

Cue Biopharma reported an EPS of -$0.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.667%.

Which hedge fund is a major shareholder of Cue Biopharma?

Currently, no hedge funds are holding shares in CUE

Cue Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-221.66%

Trailing 12-Months

Asset Growth

-58.75%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cue Biopharma

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.